Video: Every Case Tells a Story| Webinar: ACR/CHEST ILD Guidelines in Practice

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • QA/QI
    • Technology
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Researcher Studies Ways to Cut Cardiovascular Disease Risk in Rheumatoid Arthritis Patients

Staff  |  Issue: June 2013  |  June 1, 2013

Christie Bartels, MD, MS
Christie Bartels, MD, MS

In an effort to improve the prevention of cardiovascular disease (CVD) in patients with rheumatoid arthritis (RA), one researcher is taking a close look at communication between RA patients, primary care physicians, and rheumatologists.

Previous research has shown that RA patients are at a 60% greater risk of CVD events, including death, and that despite more clinic visits, RA patients have lower rates of preventive screenings, such as cholesterol tests, compared to general medical patients.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Christie Bartels, MD, MS, assistant professor of medicine, rheumatology, at the University of Wisconsin School of Medicine and Public Health in Madison, hopes that her ongoing research will result in more proactive partnerships between rheumatologists and primary care physicians to help RA patients modify their risk factors, and ultimately prevent CVD.

“My research aims to address how we can manage the heart-disease risk factors that are modifiable, like blood pressure and cholesterol count, to help RA patients receive the survival gains that the general population has seen in the last decades,” says Dr. Bartels, who received a Bridge Funding Award from the Rheumatology Research Foundation to help fund her research.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

The Bridge Funding Award allowed Dr. Bartels to adequately prepare for her three-year-long study while waiting on funding from a scored National Institutes of Health–National Institute of Arthritis and Musculoskeletal Diseases K23 grant. She presented results from the first year of her research at a recent ACR meeting.

Using a data set of local patients receiving regular care in a large health system, Dr. Bartels studied patients who had not yet been diagnosed with hypertension despite high blood pressure readings.

“I tested the hypothesis that RA patients would be less likely to get a diagnosis, or it would take longer for them to be diagnosed,” Dr. Bartels says. “We found that was true, and despite frequent visits to their clinicians, RA patients were almost 30% less likely to get a new hypertension diagnosis.”

In earlier work, Dr. Bartels found that patients who regularly visited a primary care physician were slightly more likely to get lipid testing than those who saw a rheumatologist only, but they were still less likely than the average Medicare patient to get tested.

“So it seemed that seeing a primary care physician alone might not be adequate and we might need active partnerships between rheumatologists and primary care physicians to deliver the high level of care that is needed for this population,” she says.

Page: 1 2 | Single Page
Share: 

Filed under:From the College Tagged with:Cardiovascular diseasepatient communicationRARheumatoid arthritis

Related Articles

    Better Blood Pressure Screening Needed to Manage Cardiovascular Disease Risk in Rheumatoid Arthritis

    October 3, 2014

    Study finds hypertensive patients with RA less likely to be diagnosed with high blood pressure than non-RA patients

    Study Finds NSAIDs Raise Heart Disease Risk in Osteoarthritis Patients

    February 16, 2021

    In a controlled, large-cohort, longi­tudinal study from Canada, Atiquazzaman et al. found that use of non-steroidal anti-inflammatory drugs (NSAIDs) substantially contributes to increased cardiovascular disease risk among people with osteoarthritis (OA).1  This is the first study to evaluate the mediating role that NSAIDs play in the association between OA and cardiovascular disease (CVD), and the…

    Biomarkers, Genetic Clues to Higher Cardiovascular Disease Risk in Patients with Lupus

    April 20, 2017

    WASHINGTON, D.C.—Experts at the 2016 ACR/ARHP Annual Meeting session, Systemic Lupus Erythematosus—Clinical Aspects and Treatment IV: Biomarkers, reported on a number of recent studies showing advancement in our understanding of the disease mechanisms underlying systemic lupus erythematosus (SLE) that place these patients at risk for cardiovascular disease (CVD) and other comorbidities. Mechanisms of CVD Risk…

    Long-Term Benefits, Risks of Biologic Disease-Modifying Anti-Rheumatic Drugs in Patients with RA

    December 19, 2017

    Two decades have passed since the first biologic disease-modifying anti-rheumatic drug (bDMARD) was approved. Studies on the long-term use of biologics in different disease states, such as for cardiovascular disease (CVD) and malignancy, as well as for knee/hip replacement, reveal some encouraging news. In clinical trials, bDMARDs have been shown to increase the risk of…

  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences